The Hormone That Peaks at 25 and Never Comes Back

Adrenopause: The Aging Clock in Your Adrenal Glands

In endocrinology, menopause and andropause receive most of the attention. But a third hormonal transition — adrenopause — unfolds silently over five decades, beginning in the mid-20s and proceeding without obvious symptoms until its cumulative effects become impossible to ignore. It is defined by the progressive, near-linear decline of dehydroepiandrosterone (DHEA) and its sulfated storage form DHEA-S, secreted by the zona reticularis of the adrenal cortex.

At their peak around age 25, serum DHEA-S levels typically reach 300–500 µg/dL in men and 200–380 µg/dL in women. By age 75, those same individuals will average 60–80 µg/dL — a reduction exceeding 80%. The trajectory is remarkably consistent across sexes, ethnicities, and health status, making adrenopause one of the most reproducible biological aging clocks we have identified.

What drives this decline is structural: the zona reticularis, the innermost layer of the adrenal cortex responsible for DHEA synthesis, undergoes progressive atrophy with age. Unlike the gonadal axes, adrenal androgen production is not regulated by a clear feedback loop that compensates for the decline. There is no "adrenal menopause hormone" that spikes in response. The fall is simply progressive and uncompensated.

The physiological relevance of this decline was most compellingly framed by epidemiological data from the Baltimore Longitudinal Study of Aging and the TELECOM cohort study in France, both of which demonstrated that higher DHEA-S levels in older adults were independently associated with lower all-cause mortality, cardiovascular events, and cognitive decline. Whether DHEA-S is merely a biomarker of biological robustness or a causal factor remains the central debate in the field.

Biochemistry: DHEA as Hormonal Raw Material

The Precursor Cascade

DHEA is a C19 steroid synthesized from cholesterol via pregnenolone, catalyzed by CYP17A1 (17α-hydroxylase/17,20-lyase) in adrenal zona reticularis cells. It is immediately sulfated to DHEA-S by SULT2A1, which dramatically increases its half-life from 15–30 minutes to 7–10 hours and raises circulating concentrations 300–500-fold. DHEA-S acts as a stable reservoir, desulfated peripherally on demand by steroid sulfatase (STS) enzymes expressed in liver, skin, adipose tissue, brain, and reproductive organs.

Once desulfated to DHEA, peripheral conversion proceeds via two routes depending on tissue type and sex. In men, the primary conversion is DHEA → androstenedione → testosterone, catalyzed by 3β-HSD and 17β-HSD. In women — particularly postmenopausal women — this conversion becomes disproportionately significant. Because ovarian estrogen production ceases at menopause, the adrenal-derived intracrine pathway (DHEA → testosterone → estradiol via aromatase in breast and bone) provides the majority of residual sex steroids in peripheral tissues. Labrie and colleagues estimated this pathway accounts for 40–75% of all active androgens and estrogens in postmenopausal women.

DHEA-S: The Preferred Clinical Marker

For clinical assessment of adrenal androgen status, DHEA-S is the preferred biomarker over free DHEA for several reasons. Its longer half-life produces stable serum levels with minimal diurnal variation, eliminating the need for timed draws. Reference ranges are well-established by sex and decade. A DHEA-S below the lower quartile for age — not merely the broad "normal range" that includes 80-year-old references — is more clinically meaningful when evaluating a 55-year-old with fatigue, low libido, or poor immune recovery.

DHEA as a Neurosteroid

Beyond its role as a sex hormone precursor, DHEA and DHEA-S function as neurosteroids synthesized directly in the brain and spinal cord. DHEA-S acts as a positive allosteric modulator of NMDA glutamate receptors and a negative modulator of GABA-A receptors — essentially opposing the neuroinhibitory effects of progesterone and its metabolites. Brain DHEA concentrations decline more steeply than serum levels, raising questions about whether neurocognitive aging is partly a neurosteroid deficiency state.

Clinical Evidence: What the Research Actually Shows

Bone Density — Postmenopausal Women (Labrie Studies)

The strongest human data for DHEA supplementation comes from Fernand Labrie's group at Laval University. Their 2009 randomized, double-blind, placebo-controlled trial published in Menopause examined 75 mg/day percutaneous DHEA cream (equivalent to approximately 7.5 mg systemically absorbed) in 280 postmenopausal women over 12 months. Lumbar spine bone mineral density (BMD) increased by 1.7% in the DHEA group versus no change in placebo (p = 0.02). Hip BMD improvements were smaller but directionally consistent. Mechanistically, intracrine conversion of DHEA to estradiol in bone tissue stimulates osteoblast activity and suppresses osteoclast-mediated resorption without substantially raising systemic estrogen levels — a potentially safer route than oral estrogen for women with hormone-sensitive risk factors.

Vaginal Atrophy — FDA-Approved Indication

Intravaginal DHEA (prasterone, brand name Intrarosa) was FDA-approved in 2016 for moderate-to-severe dyspareunia due to postmenopausal vulvovaginal atrophy (VVA). The approval was based on Phase III trials showing clinically significant improvements in vaginal cell maturation index, vaginal pH, and patient-reported pain scores with 0.5% prasterone suppositories (6.5 mg DHEA) administered nightly. Crucially, systemic absorption was minimal — serum estradiol and testosterone remained within the postmenopausal reference range — addressing the primary regulatory concern about systemic estrogenization. This represents the only FDA-approved indication for DHEA and provides the strongest evidence base for the intracrine conversion model.

Immune Function — NK Cell Activity

DHEA's immunomodulatory effects have been a research focus since Regelson and Kalimi's pioneering work in the 1990s. Both in vitro and animal studies consistently showed DHEA enhanced natural killer (NK) cell cytotoxicity, interleukin-2 production, and thymic function while antagonizing cortisol's immunosuppressive effects. Human data is more modest but directionally consistent. A randomized trial by Khorram et al. (1997) in elderly subjects given 50 mg/day oral DHEA for 20 weeks demonstrated a 22% increase in NK cell number and a significant rise in NK cytotoxicity. The mechanism appears to involve DHEA's role as a functional anti-glucocorticoid — higher DHEA:cortisol ratios correlate with better preserved immune responses under stress, a ratio that deteriorates substantially with age.

Cognitive Function — Mixed but Suggestive

The cognitive evidence for DHEA is the most contested in the field. Observational data is compelling: the MacArthur Studies of Successful Aging found that higher DHEA-S levels predicted better cognitive and physical function 7 years later in a cohort of 70-to-79-year-olds. Mechanistically, DHEA-S's NMDA-potentiating activity supports long-term potentiation, the electrophysiological correlate of memory formation.

Intervention trials, however, have been inconsistent. The Mayo Clinic's DHEA and testosterone trial (Nair et al., NEJM 2006) enrolled 87 men (aged 60–80) and 57 women (aged 55–75) in a randomized placebo-controlled study of DHEA 75 mg/day for 2 years. Cognitive outcomes showed no statistically significant benefit for either sex, though the study was not powered for cognitive endpoints. Earlier work by Wolkowitz and colleagues (1999) in depressed patients showed significant improvements in depressive symptoms and memory with 90 mg/day DHEA, though this was a psychiatric population with likely higher baseline impairment.

Cardiovascular Effects — DHEA and HDL

The cardiovascular epidemiology of DHEA is bidirectional and context-dependent. Multiple cross-sectional and prospective studies — including data from the TELECOM Study and the Massachusetts Male Aging Study — found inverse associations between DHEA-S levels and cardiovascular event risk in men, even after controlling for traditional risk factors. In women, the data is less consistent, with some studies suggesting U-shaped relationships at very high DHEA-S levels.

Mechanistically, DHEA supplementation consistently raises HDL cholesterol in RCTs, with the Nair NEJM trial reporting a significant increase in HDL in women at 75 mg/day. DHEA also appears to favorably modulate endothelial nitric oxide synthase (eNOS) activity and reduce vascular smooth muscle proliferation in vitro. However, no prospective randomized trial has been powered to evaluate hard cardiovascular endpoints with DHEA supplementation, leaving the clinical relevance uncertain.

Evidence Summary Table

7-Keto DHEA: The Non-Androgenic Alternative

7-Keto DHEA (3-acetyl-7-oxo-dehydroepiandrosterone) is a naturally occurring metabolite of DHEA that forms via oxidation at the C-7 position. Unlike its parent compound, 7-Keto DHEA cannot be converted back to testosterone or estradiol — the ketone group at C-7 blocks the enzymatic steps required for sex hormone conversion. This makes it fundamentally different from standard DHEA in its risk profile, particularly relevant for individuals with hormone-sensitive cancers, polycystic ovary syndrome (PCOS), or those unwilling to accept androgenic side effects.

Thermogenic Mechanism

7-Keto's primary studied mechanism is thermogenic: it activates three hepatic enzymes — fatty acyl CoA oxidase, malic enzyme, and glycerol-3-phosphate dehydrogenase — that increase the rate of fatty acid oxidation and thermogenesis. In animal models, this translates to measurable increases in resting metabolic rate (RMR). In the key human trial (Zenk et al., 2002, Current Therapeutic Research), 30 overweight adults supplementing 100 mg twice daily for 8 weeks alongside a calorie-restricted diet and exercise program lost significantly more body weight (2.88 kg vs. 0.97 kg placebo) with a concurrent rise in RMR — a finding notable because dieting typically suppresses RMR, not increases it.

Immune Modulation

7-Keto DHEA shares some of DHEA's immunomodulatory properties through non-hormonal pathways, including enhancement of IL-2 production and thymic activity. Registered research in clinical trial databases suggests ongoing investigation into 7-Keto for immune senescence, though the human evidence base remains smaller than for standard DHEA.

Safety and Cortisol

Unlike DHEA, 7-Keto does not suppress the HPA axis or convert to cortisol precursors. It has a cleaner safety profile in the existing literature, with no androgenic side effects reported in controlled studies. This makes it attractive for postmenopausal women concerned about androgenic acne or voice deepening, and for men on testosterone replacement who want to avoid stacking additional androgenic substrate.

Adrenal Function vs. Exogenous DHEA: The Suppression Question

One of the primary clinical concerns with oral DHEA supplementation is adrenal suppression. Standard DHEA enters the systemic circulation, raising serum levels that may — in theory — signal via feedback loops to reduce endogenous adrenal production. In practice, the evidence for meaningful HPA suppression from typical 25–50 mg oral doses is limited. Unlike cortisol, whose negative feedback on the hypothalamic-pituitary axis is well-characterized, DHEA lacks a defined negative feedback loop equivalent. The adrenal zona reticularis does not appear to downregulate DHEA output in response to exogenous DHEA at physiological supplementation doses.

Nonetheless, supraphysiological doses (>100 mg/day oral) could theoretically alter ACTH-adrenal dynamics, and chronic high-dose use without monitoring is inadvisable. More practically, high-dose oral DHEA in women can produce androgenic side effects — acne, facial hair growth, oily skin — because peripheral conversion to testosterone occurs in skin and hair follicles. In men, conversion to estradiol via aromatase can theoretically raise estrogen levels, though this is rarely problematic at 25–50 mg doses.

The Testing Imperative

Testing serum DHEA-S before initiating supplementation is arguably the single most important decision point. DHEA-S is a straightforward, inexpensive blood test available from any commercial lab. A 50-year-old with DHEA-S of 180 µg/dL (in the mid-range for age) has a fundamentally different risk-benefit calculation than a 50-year-old with DHEA-S of 40 µg/dL (in the lowest quartile). Supplementing without testing means potentially raising an already-adequate level into supraphysiological territory, increasing androgenic side effect risk for no marginal benefit.

Follow-up testing at 6–8 weeks after initiating supplementation allows dose titration to target DHEA-S in the upper-normal range for the patient's biological sex and age rather than simply the laboratory reference range, which often pools across all adult decades.